Amyotrophic lateral sclerosis (ALS): Three letters that change the people's life. For ever

Arquivos de Neuro-Psiquiatria

Volumn 67, Issue 3 A, 2009, Pages 750-782

  Oliveira, Acary Souza Bulle ^a,b   Pereira, Roberto Dias Batista ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIFESP/EPM ^*  (Brazil)

Author keywords

Amyotrophic lateral sclerosis; Diagnosis; Treatment

Indexed keywords

6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ACTIVATED PROTEIN C; AEOL 10150; AMFEBUTAMONE; BOTULINUM TOXIN B; CALPASTATIN; CASPASE INHIBITOR; CEFTRIAXONE; CELECOXIB; CYCLOSPORIN A; CYSTATIN C; DEXANABINOL; ETIRACETAM; IFENPRODIL; MEMANTINE; MINOCYCLINE; MODAFINIL; NIMODIPINE; PLACEBO; RASAGILINE; RILUZOLE; ROFECOXIB; RPR 119990; SOMATOMEDIN C; SULINDAC; TALAMPANEL; TCH 346; THALIDOMIDE; TREHALOSE; TRIENTINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VINCRISTINE;

ABSENCE OF SIDE EFFECTS; ALTERNATIVE MEDICINE; AMYOTROPHIC LATERAL SCLEROSIS; ANISOTROPY; APOPTOSIS; ASSISTED VENTILATION; BLADDER FUNCTION; BONE MARROW BIOPSY; BONE MARROW TRANSPLANTATION; BRONCHOPNEUMONIA; CAREGIVER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL EXAMINATION; CLINICAL FEATURE; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CORD BLOOD STEM CELL TRANSPLANTATION; DEATH; DEGENERATIVE DISEASE; DELAYED DIAGNOSIS; DEMOGRAPHY; DEPRESSION; DETERIORATION; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DIFFUSION COEFFICIENT; DIFFUSION TENSOR IMAGING; DISEASE COURSE; DNA DAMAGE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSARTHRIA; DYSPHAGIA; DYSPNEA; EDUCATIONAL STATUS; ELECTROPHYSIOLOGY; EMOTION; ENTERIC FEEDING; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; EVIDENCE BASED PRACTICE; EXCITOTOXICITY; FACE MASK; FAMILIAL DISEASE; FAMILY COUNSELING; FATIGUE; FOOD INTAKE; GASTROTOMY; GENE LOCUS; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; GENOME ANALYSIS; HEALTH CARE PLANNING; HEREDITY; HUMAN; HYPERSALIVATION; IMMUNE SYSTEM; IMMUNOHISTOCHEMISTRY; INCIDENCE; INTERPERSONAL COMMUNICATION; INTESTINE FUNCTION; INTIMACY; KINESIOTHERAPY; LABORATORY TEST; LUNG VENTILATION; MENTAL INSTABILITY; MICROGLIA; MITOCHONDRION; MORNING DOSAGE; MOTOR NERVE; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; MUSCLE BIOPSY; MUSCLE STRETCHING; MUSCLE WEAKNESS; NEUROFILAMENT; NEUROIMAGING; NEUROPATHOLOGY; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NUTRITION; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; PAIN; PALLIATIVE THERAPY; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT CARE; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; PHLEGMON; PHYSICAL DISABILITY; PNEUMONIA; PREVALENCE; PROGNOSIS; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FOLDING; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RELIGION; RESPIRATORY FAILURE; RESPIRATORY TRACT DISEASE; REVIEW; RISK FACTOR; RNA INTERFERENCE; SEXUALITY; SMOKING; SPASTICITY; SPINAL MUSCULAR ATROPHY; SUPPORT GROUP; SURVIVAL; SYMPTOMATOLOGY; TRACHEOSTOMY; TRACHEOTOMY; TRANSGENIC MOUSE; TREATMENT DURATION; UMBILICAL CORD BLOOD; VETERAN; WAR; WORK ENVIRONMENT;

EID: 69749105655     PISSN: 0004282X     EISSN: 16784227     Source Type: Journal    
DOI: 10.1590/S0004-282X2009000400040     Document Type: Review

References (128)

1. Swash M, Desai J. Motor neuron disease: classification and nomenclature. ALS 2000;1:105-112.
2. Schiffman NI, Schiffman MG. The legacy of Lou Gehrig's disease: notable people with ALS. In: Belsh JM, Schiffman PL (Eds). Amyotrophic lateral sclerosis: diagnostic and management for the clinician. Armonk, NY: Futura 1996:219-256.
3. Eisen AA. Historical aspects of motor neuron diseases. In: Eisen AA, Shaw PJ (Eds). Handbook of Clinical Neurology. Motor Neuron Disorders and Related Diseases. Elsevier 2007;82:1-12.
4. Lambert EH, Mulder DW. Electromyographic studies in amyotrophic lateral sclerosis. Mayo Clinic Proc 1957;32:441.
5. Subcommittee on Motor Neuron Diseases / Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial "Clinical Limits of Amyotrophic Lateral Sclerosis" Workshop contributors. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. J Neurol Sci 1994;124:96-107.
6. World Federation of Neurology Research Group on Neuromuscular Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral dclerosis. HYPERLINK http://www.wfnals.org/articles/elescorial1998.htm
7. Ross MA, Miller RG, Berchert L, et al. Toward earlier diagnosis of amyotrophic lateral sclerosis. Revised criteria. Neurology 1998;50:768-772.
8. Nodera H, Izumi Y, Kaji R. New diagnostic criteria of ALS: Awaji criteria. Brain and nerve = Shinkei Kenkyu no Shinpo 2007;59:1023-1029. (Pubitemid 47603088)
9. Traynor BJ, Codd MB, Corr B, et al. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57:1171-1176. (Pubitemid 30644664)
10. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes. A population-based study. Arch Neurol 2000;57:109-113.
11. Rocha AJ, Martins Júnior AC, Nogueira RG, Lederman HM. Magnetic resonance findings in amyotrophic lateral sclerosis using a spin echo magnetization transfer sequence. Arq Neuropsiquiatr 1999;57:912-915.
12. Garcia LN, Silva, AV, Carrete HJr, Fávero, FM, Fontes SV, Monero MT, Oliveira ASB. Relação entre degeneração do trato córtico-espinhal através de ressonância magnética e escala funcional (ALSFRS) em pacientes com esclerose lateral amiotrófica. Arq Neuropsiquiatr 2007;65:869-874.
13. Chieia MAT. Esclerose lateral amiotrófica: consideraç ões a respeito dos critérios diagnósticos. Tese de mestrado em neurociências, Universidade Federal de São Paulo/Escola Paulista de Medicina, 2008.
14. Donaghy M. Classification and clinical features of motor neuron diseases and motor neuropathies in adults. J Neurol 1999;246:331-333. (Pubitemid 29261419)
15. Leigh PN, Swash M, Iwasaki Y, et al. Amyotrophic lateral sclerosis: a consensus viewpoint on designing and implementing a clinical trial. ALS 2004;5:84-98. (Pubitemid 39545336)
16. Armon C. Epidemiology of amyotrophic lateral sclerosis/motor neuron disease. In: Shaw PJ, Strong MJ (Eds). Motor neuron disease (Blue Book): Butterworth-Heinemann, Philadelphia 2003:167-205.
17. Dengler R. Current treatment pathways in ALS, a European perspective. Neurology 1999;53(Suppl):S4-S10. (Pubitemid 29530306)
18. Rosen DR, Siddique T, Patterson D, et al. Mutations in Cu/Zn super oxide dismutase are associated with familial amyotrophic lateral sclerosis. Nature 1993;362:59-62. (Pubitemid 23087289)
19. Shaw CE, Enayat ZE, Chioza BA, et al. Mutations in all five exons of SOD-1 may cause ALS. Ann Neurol 1998;43:390-394.
20. Andersen P. The genetics of ALS/MND and the role of modifier genes: a clinical perspective. ALS 2007;8:7-8.
21. Veldink JH, Van den Berg L, Wokke JHJ. The future of motor neuron disease. J Neurol 2004;251:491-500.
22. Nihimura AL, Mitne-Neto M, Silva HCA, et al. A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and ALS. Am J Human Genet 2004;5:822-831. (Pubitemid 39390489)
23. Andrews J. Amyotrophic lateral sclerosis: clinical management and research update. Curr Neurol Neurosci Rep 2009;9:59-68.
24. Ellison D, Love S, Chimelli L, Harding BN, Lowe J, Vinters HV. Motor neuron disorders. In: Ellison D, Love S, Chimelli L, Harding B, Lowe JS, Vinters H (Eds). Neuropathology: a reference text of CNS pathology, (Ed2) 2004:501-510.
25. Al-Chalabi A, Leigh PN. Recent advances in amyotrophic lateral sclerosis. Curr Opin Neurol 2000;13:397-405. (Pubitemid 30679229)
26. Shaw CE, Al-Chalabi A, Leigh N. Progress in the pathogenesis of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 2001;1:69-76.
27. Martin LJ. Neuronal death in amyotrophic lateral sclerosis is apoptosis possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999;58:459-471. (Pubitemid 29220739)
28. Sathasivam S, Ince PG, Shaw PJ. Apoptosis in amyotrophic lateral sclerosis: a review of the evidence. Neuropathol Appl Neurobiol 2001:27:257-274. (Pubitemid 32758614)
29. Gonzalez de Aguilar JL, Echaniz-Laguna A, Fergani A, et al. Amyotrophic lateral sclerosis: all roads lead to Rome. J Neurochem 2007;101:1153-1160. (Pubitemid 46718806)
30. CVE - Centro de Vigilância Epidemiológica. Síndrome pós-poliomielite. [Orientações para profissionais de saúde]. São Paulo: SES/SP; 2008. In: ftp://ftp.cve.saude.sp.gov.br/ doc-tec/hidrica/doc/SPP08-manual.pdf
31. Sánchez AME, Mejia-Toiber J, Massieu L. Excitotoxic neuronal death and the pathogenesis of Huntington's disease. Arch Med Res 2008;39: 265-276. (Pubitemid 351221151)
32. Ross CA, Poirier MA. Opinion: what is the role of protein aggregation in neurodegeneration? Nat Rev Mol Cell Biol 2005;6:891-898.
33. Tartaglia GG, Cavalli A, Pellarin R, Caflisch A. Prediction of aggregation rate and aggregation-prone segments in polypeptide sequences. Protein Sci 2005;14:2723-2734. (Pubitemid 41395598)
34. Gupta S, Agrawal A, Agrawal S, Su H, Gollapudi S. Immunity Ageing 2006;3:5.
35. Strasser A. The role of BH3-only proteins in the immune system. Nat Rev Immunol 2005;5:189-200. (Pubitemid 40364821)
36. Akhlaq A, Wei-Yi FO, Horrocks L. Neurochemical Aspects of Excitotoxicity. Springer 2008.
37. Appel SH, Engelhardt JI, García J, Stefani E. Immunoglobulins from animal models of motor neuron disease and from human amyotrophic lateral sclerosis patients passively transfer physiological abnormalities to the neuromuscular junction. Proc Natl Acad Sci 1991;88:647-651. (Pubitemid 21915523)
38. Maarten D, Ludo VDB, Robberecht W. Microglia in amyotrophic lateral sclerosis. Acta Neurol Belg 2007;107:63-70.
39. Morahan JM, Yu B, Trent RJ, Pamphlett R. Genetic susceptibility to environmental toxicants in ALS. Amer Genet 2007;144:885-890. (Pubitemid 47547988)
40. Bradley W. New aspects of the cyanobacteria/BMAA hypothesis and future directions. ALS 2008;9:40.
41. Chen A, Montes J, Mitsumoto H. The role of exercise in amyotrophic lateral sclerosis. Physical medicine and rehabilitation. Clin North Amer 2008;19:545-557. (Pubitemid 351952446)
42. Piazza O, Siren AL, Ehrenreich H. Curr Med Res Opinion 2004;20:505-508.
43. Taioli E. All causes mortality in male professional soccer players. Eur J Pub Health, Advance Access published online on April 12, 2007;1-5. (Pubitemid 350274566)
44. Chiò A, Traynor BJ, Swingler R, et al. Amyotrophic lateral sclerosis and soccer: a different epidemiological approach strengthen the previous findings. J Neur Sci 2008;269:187-189. (Pubitemid 351626085)
45. Sutedja NA, Veldink JH, Fischer K, et al. Lifetime occupation, education, smoking, and risk of ALS. Neurology 2007;69:1508-1514. (Pubitemid 47537857)
46. Horner RD, Kamins KG, Feussner JR, et al. Occurrence of amyotrophic lateral sclerosis among Gulf War veterans. Neurology 2003;61:742-749.
47. Chiò A, Logroscino G, Hardiman O, et al. Prognostic factors in ALS: a critical review. ALS 2008;5:1-14.
48. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. ALS 2005;6:37-44.
49. de Carvalho M, Dengler R, Eisen A, et al. Electrodiagnostic criteria for diagnosis of ALS: consensus of an International Symposium sponsored by IFCN. Clin Neurophysiol 2008;119:497-503.
50. Gutierrez J, Zaldivar T, Lara G, et al. Distal vs proximal muscle involvement pattern in patients with early-stage amyotrophic lateral sclerosis. Clin Neurophysiol 2008;119:e125-e125.
51. Carvalho M, Chiò A, Dengler R, Hecht M, Weber M, Swash M. Neurophysiological measures in amyotrophic lateral sclerosis: markers of progression in clinical trials. ALS 2005;6:17-28. (Pubitemid 40668244)
52. Oreja-Guevara C, Rodriguez de Rivera FJ, Alonso Clarke R, Alvarez-Linera J, Diez-Tejedor E. Diffusion anisotropy imaging in amyotrophic lateral sclerosis. ALS 2007;8:134.
53. Zetterberg H, Jacobsson J, Rosengren L, Blennow K, Andersen PM. Cerebrospinal fluid neurofilament light levels in amyotrophic lateral sclerosis: impact of SOD1 genotype. Eur J Neur 2007;14:1329-1333. (Pubitemid 350135296)
54. Bowser R, Ryberg H, Wilson M, Darko S, Lacomis D. Protein biomarkers for ALS disease progression. ALS 2008;9:10-11.
55. Brettschneider J, Mogel H, Lehmensiek V, et al. Proteome analysis of cerebrospinal fluid in amyotrophic lateral sclerosis (ALS). Neurochem 2008;33:2358-2363.
56. Traynor BJ, Codd MB, Corr B, Ford C, Frost E, Hardiman O. Incidence and prevalence of ALS. In: Ireland, 1995-1997: a population-based study. Neurolgy 1999;52:504-509.
57. Srinivasan J, Scala S, Jones HR, Saleh F, Russell JA. Inappropriate surgeries resulting from misdiagnosis of early amyotrophic lateral sclerosis. Muscle Nerve 2006;34:359-360. (Pubitemid 44300168)
58. th International Symposium on ALS/MND, Noordwijk, Holland, November, 1994.
59. Belsh JM. Diagnostic challenges in ALS. Neurology 1999;53(Suppl):S26-S30.
60. Bozeat S, Gregory CA, Ralph MAL, Hodges JR. Which neuropsychiatry and behavioral features distinguish frontal and temporal dementia from Alzheimer's disease? J Neurol Neurosurg Psychiatry 2000;68:178-186.
61. Strong MJ. The syndromes of frontotemporal dysfunction in amyotrophic lateral sclerosis. ALS 2008;9:323-338.
62. Deng HX, Siddique T. Transgenic mouse models and human neurodegenerative disorders,Arch Neurol 2000;57:1695-1702.
63. Kato S. Amyotrophic lateral sclerosis models and human neuropathology: similarities and differences. Acta Neuropathol 2008;115:97-114. (Pubitemid 50003823)
64. Radunovic A, Mitsumoto H, Leigh PN. Clinical care of patients with amyotrophic lateral sclerosis. Lancet Neurol 2007;6:913-925. (Pubitemid 47422248)
65. Bromberg M. Accelerating the diagnosis of amyotrophic lateral sclerosis. The Neurologist 1999,5:63-74. (Pubitemid 29143020)
66. Silani V, Borasio D. Honesty and hope: announcement of diagnosis in ALS. Neurology 1999;53(Suppl):S37-S39. (Pubitemid 29530314)
67. Maguire P, Fairburn S, Fletcher C. Consultation skills of young doctors. BMJ 1986;292:1573-1578.
68. rd series). Motor neuron diseases and related disorders. Elsevier 2007;375-387.
69. Traynor BJ, Brujin L, Conwit R, et al. Neuroprotective agents for clinical trials in ALS: a systematic assessment. Neurology 2006;67:20-27. (Pubitemid 44305456)
70. Shefner JM. Designing clinical trials in amyotrophic lateral sclerosis. Phys Med Rehab Clin North America 2008;19:495-508. (Pubitemid 351952445)
71. Gordon PH, Cheng B, Montes J, Doorish C, Albert SM, Mitsumoto H. Outcome measures for early phase clinical trials. ALS 2007;8:270-273. (Pubitemid 47543091)
72. Cudkowicz ME, Shefner JM, Schoenfeld D, et al. Clinical trial of celecoxib in subjects with amyotrophic lateral sclerosis. ALS 2004;5:25-26.
73. Drachman DB, Frank K, Dykes-Hoberg M, et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol 2002;52:771-778. (Pubitemid 35403187)
74. Klivenyi P, Ferrante RJ, Matthews RT, et al. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 1999;5:347-350. (Pubitemid 29124375)
75. Groeneveld GJ, Veldink JH, Van DTI, et al. A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445. (Pubitemid 36373255)
76. Gurney ME, Cutting FB, Zhai P, et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 1996;39:147-157. (Pubitemid 26071564)
77. Miller RG, Moore DH, Gelinas DF, et al. Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology 2001;56:843-848. (Pubitemid 32293584)
78. Andreassen OA, Dedeoglu A, Klivenyi P, Beal MF, Bush AI. N-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosis. Neuroreport 2000;11:2491-2493. (Pubitemid 30622295)
79. Kuther G, Struppler A. Therapeutic trial with N-acetylcysteine in amyotrophic lateral sclerosis. Adv Exp Med Biol 1987;209:281-284.
80. Bensimon G, Lacomblez L, Meininger V, and the ALS/Riluzole Study Group. A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med 1994;330:585-591.
81. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. For the amyotrophic lateral sclerosis / Riluzole Study group II. Dose-ranging study for riluzole in amyotrophic lateral sclerosis. Lancet 1996:347:1425-1431. (Pubitemid 26161204)
82. Lacomblez L, Bensimon G, Leigh PN, et al. A confirmatory dose-ranging study of riluzole in ALS. Neurology 1996;47(Suppl):S242-S250. (Pubitemid 26422577)
83. Brooks BR, Sanjak M. Disease-modifying drug therapies. ALS and other motor neuron disorders 2004;5:68-75.
84. Richard OW, Lane Russell JM, Ross M. ALS 2008;9:195-211.
85. Mitsumoto H, Chad DA, Pioro EP. Amyotrophic lateral sclerosis. Contemporary neurology series. Oxford University Press; edition 1; vol.49, 1998.
86. Bello-Haas VD, Florence JM, Kloos AD, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 2008;71:864-865.
87. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 2004;3:205-214.
88. Chiappetta ALML, Oda AL, Oliveira ASB. Doença do neurônio motor. In PROCLIM - Programa de Atualização em Clínica Médica. Artmed (ed), 2005:105-135.
89. Jackson C, Gronseth G, Rosenfeld J, et al. Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients. Muscle Nerve 2009;39:137-143.
90. Stanich P, Pereira AML, Chiappetta ALML, Nunes M, Oliveira ASB, Gabbai AA. Suplementação nutricional em pacientes com doença do neurônio motor/esclerose lateral amiotrófica. Rev Bras Nut Clín 2004;19:70-77.
91. Hartmann S, Van Der Weg B, Binek J, Knoblauch A, Meyenberger C, Weber M. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis: role of BiPAP ventilation. ALS 2007;8:79.
92. Corcia P, Pradat PF, Salachas F, et al. Causes of death in a post-mortem series of ALS patients. ALS 2008;9:59-62. (Pubitemid 351260374)
93. Perrin C, Unterborn JN, D'Ambrosio C, Hill NS. Pulmonary complications of chronic neuromuscular disease and their management. Muscle Nerve 2004;29:5-27. (Pubitemid 38040552)
94. Takada H, Oyama Y, Kon S. Artificial ventilatory management in long-term hospitalized patients with amyotrophic lateral sclerosis at a Japanese Hospital for chronic neuromuscular disoders. ALS 2007;8:85-86.
95. Bourke SC, Tomlinson M, Williams TL, et al. Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis. Lancet Neurol 2006;5:140-147.
96. Onders R, Katirji B, Elmo M, et al. Results of prospective pilot and multi-center pivotal trials of diaphragm pacing in amyotrophic lateral sclerosis: maintaining diaphragm function and improving survival. ALS 2008;9:54-55.
97. Miller RG, Rosenberg JA, Gelinas DF, et al. Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the quality standards subcommittee of the American Academy of Neurology. Neurology 1999;52:1311-1323.
98. Nolan MT, Hughes M, Narendra DP, et al. When patients lack capacity: the role that patients with terminal diagnoses would choose for their physicians and loved ones in making medical decisions. J Pain Symptom Management 2005;30:342-353. (Pubitemid 41527120)
99. Murphy PL, Albert SM, Weber C, Del Bene ML, Rowland LP. Impact of spirituality and religiousness on outcomes in patients with ALS. Neurology 2000;55:1581-1584.
100. Borasio GD. Meditation and ALS. In: Mitsumoto H, Munsat T (Eds). Amyotrophic lateral sclerosis: a comprehensive guide to management. Demos Medical Publishing, New York, 2001;271-276.
101. Gordon PH, Mitsumoto H. Syntomatic therapy and palliative aspects of clinical care. In: Eisen AA, Shaw PJ (Eds). Handbook of Clinical Neurology. Vol.82 (3rd series) Motor neuron disorders and related diseases. Elsevier, New York, 2007;389-424.
102. Mitsumoto H, Rabkin JG. Palliative care for patients with amyotrophic lateral sclerosis: "prepare for the worst and hope for the best". JAMA 2007;298:207-216.
103. Fried-Oken M, Fox L, Rau M, Tullman J, Baker G, Lou J. Purposes of AAC device use for persons with ALS as reported by caregivers. Augmentative Alternative Communication 2006,20:209-221. (Pubitemid 44350010)
104. National Center for Complementary and Alternative Medicine (NCCAM). What is CAM? NCCAM Publication; No. D347. Available at http://nccam.nih.gov/health/ whatiscam. Updated February 2007.
105. Leirvik A, Liverod M, Holmoy T. Quality of life of patients with amyotrophic lateral sclerosis. Tidsskr Nor Laegeforen 2006;126:2520-2522. (Pubitemid 44536685)
106. Lanka V, Cudkowicz M. Therapy development for ALS: lessons learned and path forward. ALS 2008;9:131-140. (Pubitemid 351983173)
107. Gordon PH, Moore DH, Miller RG, et al. Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurol 2007;6:1045-1053.
108. Silani V, Cova L, Corbo M, Ciammola A, Polli E. Stem-cell therapy for amyotrophic lateral sclerosis. Lancet 2004;364:200-202. (Pubitemid 38891692)
109. Mazzini L. Told the 13th International Symposium on Motor Neurone Disease in Melbourne. J Neurosci Res 2002;15;69:908-917.
110. Mazzini L, Fagioli F, Boccaletti R, et al. Stem cell therapy in amyotrophic lateral sclerosis: a methodological approach in humans. ALS 2003;4:158-161. (Pubitemid 37184884)
111. Mazzini L, Mareschi K, Ferrero I, et al. Stem cell treatment in amyotrophic lateral sclerosis. J Neurol Sci 2008;265:78-83.
112. Suzuki M, McHugh J, Tork C, et al. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Molec Therapy 2008;16: 2002-2010.
113. Suzuki M, Svendsen CN. Combining growth factor and stem cell therapy for amyotrophic lateral sclerosis. Trends Neurosci 2008;31:192-198.
114. Van den Berg L. Unproven cell-based treatments for ALS/MND: lessons from Beijing. ALS 2007;8:32.
115. Chew S, Khandji AG, Montes J, Mitsumoto H, Gordon PH. ALS 2007;8:314-316.
116. Fornai F, Longone P, Ferrucci M, et al. Autophagy and ALS: the multiple roles of lithium. Autophagy 2008;4:527-530.
117. Fornai F, Longone P, Lenzi P, et al. Lithium delays progression of ALS. Proc Natl Acad Sci 2008;105:2052-2057.
118. Wicks P, Massagli M, Frost J, Macedo H, Felzer K, Heywood J. A patient-led trial of lithium in ALS using the internet. ALS 2008;9:59.
119. Pizzasegola C, Caroni I, Daleno C, Carrì MT, Bendotti C. Lithium carbonate treatment does not improve the disease progression in two different strains of SOD1 mutant mice. ALS 2008; SW262.
120. Meininger V, Shefner J, Cudkowicz M. Lithium therapy in ALS. ALS 2008;9:122.
121. Waldmeier PC. Prospects for antiapoptotic drug therapy of neurodegenerative diseases. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27:303-321. (Pubitemid 36351497)
122. Cudkowicz ME, Shefner JM, Elizabeth S, et al. Arimoclomol at dosages up to 300 mg/day is well tolerated and safe in amyotrophic lateral sclerosis. Muscle Nerve 2008;38:837-844.
123. Yamamoto M, Fumiaki T, Hiroshi T, Gen S. A strategy for developing effective amyotropic lateral sclerosis pharmacotherapy: from clinical trials to novel pharmacotherapeutic strategies. Expert Opin Pharmacother 2008;9:1845-1857.
124. Koen P, Diether L, Philip VD, et al. Novel role for vascular endothelial growth factor (VEGF) receptor-1 and its Ligand VEGF-B in motor neuron degeneration. J Neurosci 2008;28:10451-10459.
125. Liu HNS, Tjostheim S, Horne P, et al. Immunization strategy for treating amyotrophic lateral sclerosis that targets misfolded SOD1.ALS 2007; 1:150.
126. Kaspar BK, Llado J, Sherkat N, Rothstein JD, Gage FH. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 2003;301:839-842. (Pubitemid 36962626)
127. Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101:2963-2972. (Pubitemid 36857981)
128. Christou YA, Moore HD, Shaw PJ, Monk PN. Embryonic stem cells and prospects for their use in regenerative medicine approaches to motor neurone disease. Neuropathol Appl Neurobiol 2007;33:485-498.